Corcept Therapeutics Incorporated
CORT
株式のランク
#1761
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
株価
$112.72
最終同期: 2026-10-19
時価総額
$12.18B
変化（1日）
2.32%
変化（1年）
43.41%
国
US
取引 Corcept Therapeutics Incorporated (CORT)
カテゴリー
Healthcare
Corcept Therapeutics Incorporated（CORT）のP/B比率
October 2026 時点のP/B比率 TTM: 17.35
Corcept Therapeutics Incorporated の最新の財務報告および株価によると、現在のP/B比率（TTM）は 17.35 です。2023 年末時点でのP/B比率は 6.64 でした。
Corcept Therapeutics Incorporated の P/B 比率の履歴（2001 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 17.35 | 126.85% |
| 2024 | 7.65 | 15.31% |
| 2023 | 6.64 | 53.60% |
| 2022 | 4.32 | -29.07% |
| 2021 | 6.09 | 5.62% |
| 2020 | 5.77 | 54.77% |
| 2019 | 3.73 | -38.76% |
| 2018 | 6.09 | -43.31% |
| 2017 | 10.74 | -44.66% |
| 2016 | 19.40 | -32.53% |
| 2015 | 28.75 | -132.16% |
| 2014 | -89.41 | -686.49% |
| 2013 | 15.25 | 608.08% |
| 2012 | 2.15 | -73.70% |
| 2011 | 8.19 | -34.07% |
| 2010 | 12.42 | 88.15% |
| 2009 | 6.60 | 134.13% |
| 2008 | 2.82 | -60.76% |
| 2007 | 7.18 | 62.61% |
| 2006 | 4.42 | 42.36% |
| 2005 | 3.10 | 23.71% |
| 2004 | 2.51 | -75.71% |
| 2003 | 10.33 | -375.72% |
| 2002 | -3.75 | -227.48% |
| 2001 | 2.94 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| 3.8424 | -77.86% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 2.4753 | -85.74% |
HK
|
